drugset / Trial / NCT05077540
Oxytocin Versus, Sublingual Misoprostol in the Secondary Prevention of Postpartum Hemorrhage After Vaginal Delivery
RandomizedParallel-groupQuadruple-blindPrevention
Summary
Researchers sought to see how oxytocin versus, sublingual misoprostol affected estimated and measured blood loss during vaginal delivery in women who had blood loss \>300 ml .
Timeline
- Start
- 2021-11-01
- Primary completion
- 2023-10-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Misoprostol | Other / unclassified | 800 ug | Other |
| Comparator | Oxytocin | Peptide | 20 iu | Other |
Indications
No indication recorded.